Michael Bavaro Sells 30,996 Shares of Option Care Health, Inc. (NASDAQ:OPCH) Stock

Option Care Health, Inc. (NASDAQ:OPCH - Get Free Report) insider Michael Bavaro sold 30,996 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the transaction, the insider now directly owns 44,974 shares in the company, valued at approximately $1,495,835.24. This trade represents a 40.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Option Care Health Price Performance

Option Care Health stock traded down $0.08 during trading on Friday, reaching $34.18. The company had a trading volume of 443,502 shares, compared to its average volume of 1,587,298. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.32 and a current ratio of 1.73. The firm's 50-day simple moving average is $29.61 and its 200 day simple moving average is $28.18. The firm has a market capitalization of $5.65 billion, a PE ratio of 28.80, a price-to-earnings-growth ratio of 2.30 and a beta of 1.33. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $34.85.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on OPCH shares. UBS Group initiated coverage on Option Care Health in a report on Thursday, December 5th. They issued a "neutral" rating and a $26.00 target price for the company. Barrington Research boosted their price objective on shares of Option Care Health from $33.00 to $38.00 and gave the stock an "outperform" rating in a research note on Thursday, February 27th. Jefferies Financial Group raised shares of Option Care Health from a "hold" rating to a "buy" rating and lifted their price target for the stock from $26.00 to $35.00 in a report on Thursday, January 23rd. JPMorgan Chase & Co. raised their price objective on Option Care Health from $40.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday. Finally, Bank of America upgraded Option Care Health from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $26.00 to $33.00 in a research note on Monday, January 13th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $33.00.

Remove Ads

Institutional Investors Weigh In On Option Care Health

Several large investors have recently bought and sold shares of OPCH. Raymond James & Associates boosted its stake in shares of Option Care Health by 6.3% in the third quarter. Raymond James & Associates now owns 85,279 shares of the company's stock worth $2,669,000 after acquiring an additional 5,049 shares during the last quarter. International Assets Investment Management LLC boosted its stake in Option Care Health by 3,029.7% during the 3rd quarter. International Assets Investment Management LLC now owns 2,848 shares of the company's stock worth $91,000 after purchasing an additional 2,757 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Option Care Health during the third quarter worth $206,000. State of Alaska Department of Revenue raised its position in shares of Option Care Health by 3.8% in the third quarter. State of Alaska Department of Revenue now owns 19,871 shares of the company's stock valued at $621,000 after buying an additional 735 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Option Care Health by 7.0% in the third quarter. Nisa Investment Advisors LLC now owns 14,526 shares of the company's stock worth $455,000 after buying an additional 945 shares in the last quarter. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.